Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Obstructive Sleep Apnoea Syndrome (Causes, Symptoms, and Treatment) article more useful, or one of our other health articles.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
Synonyms: obstructive sleep apnoea/hypopnoea syndrome
(NB: sometimes 'apnoea' is spelt 'apnea')
The widely accepted definition of obstructive sleep apnoea syndrome (OSAS) is a clinical condition in which there is intermittent and repeated upper airway collapse during sleep. This results in irregular breathing at night and excessive sleepiness during the day.
- Complete apnoea is defined as a ten-second pause in breathing activity.
- Partial apnoea, also known as hypopnoea, is characterised by a ten-second period in which ventilation is reduced by at least 50%.
- Research is focusing on the concept of sleep fragmentation (the poor-quality sleep produced by repeated episodes of apnoea or hypopnoea) and objective measurements of upper airways obstruction.
OSAS is a worldwide phenomenon. The prevalence of OSAS in Western countries is around 4% in middle-aged men and around 2% in middle-aged women. The incidence is increasing as the incidence of obesity is increasing.
OSAS is highly prevalent in persons with type 2 diabetes and related metabolic conditions such as insulin resistance and glucose intolerance.
- Obesity (strongest risk factor).
- Male gender.
- Middle age (55-59 in men, 60-64 in women).
- Sedative drugs.
- Excess alcohol consumption.
- Family history.
- Possibly genetic tendency related to jaw morphology.
- Obese children - they have a higher prevalence and severity of OSAS.
A history of snoring and witnessed apnoeas with symptoms of sleep fragmentation, such as excessive daytime sleepiness, suggests OSAS.
The National Institute for Health and Care Excellence (NICE) recommends taking a sleep history and assessing people for OSAS if they have two or more of the following features:
- Witnessed apnoeas.
- Unrefreshing sleep.
- Waking headaches.
- Unexplained excessive sleepiness, tiredness or fatigue.
- Nocturia (waking from sleep to urinate).
- Choking during sleep.
- Sleep fragmentation or insomnia.
- Cognitive dysfunction or memory impairment.
Symptoms such as personality change, episodes of apnoea, irritability and restlessness at night may be better elicited by taking a history from a partner.
Daytime sleepiness is sometimes assessed using the Epworth Sleepiness Scale. Investigation is usually recommended when the score is greater than 10. However, at least 10% of the population have a score of 11 or more.
Do not use the Epworth Sleepiness Scale alone to determine if referral is needed, because not all people with OSAS have excessive sleepiness.
An urgent referral is recommended if the Epworth sleepiness score is >18 or the patient has had a road traffic incident or near miss event. Those with signs of respiratory failure or heart failure should also be referred urgently.
Urgent specialist clinic assessment should also be considered if the patient:
- Has a vocational driving job.
- Has a job for which vigilance is critical for safety.
- Has unstable cardiovascular disease - eg, poorly controlled arrhythmia, nocturnal angina or treatment-resistant hypertension.
- Is pregnant.
- Is undergoing pre-operative assessment for major surgery.
- Has non-arteritic anterior ischaemic optic neuropathy.
There are no specific diagnostic findings on examination but the following may be noteworthy:
- Fat deposition anterolateral to the upper airway may signify obstruction.
- Neck circumference is a strong predictor of OSAS (<37 cm is low-risk, >48 cm is high-risk).
- Certain craniofacial or pharyngeal abnormalities are associated with OSAS - eg, retrognathia, micrognathia, enlarged tonsils, macroglossia, thickening or lengthening of the soft palate or uvula.
- Assess for presence of nasal polyps, rhinitis or any deformity of the nose.
- Fragmented sleep (quality of sleep).
- Sleep deprivation (quantity of sleep).
- Shift work.
- Restless legs syndrome/periodic limb movement disorder.
- Stimulants (caffeine, theophyllines, amfetamines).
- Selective serotonin reuptake inhibitors (SSRIs).
- Idiopathic hypersomnolence.
- Excess alcohol.
- Neurological conditions:
OSAS is defined by five or more respiratory events (apnoeas, hypopnoeas or arousals) per hour, in association with symptoms of sleep-disordered breathing (SDB).
Clinical assessment is not sufficient to make a diagnosis of OSAS. The diagnosis of OSAS is made through different levels of nocturnal monitoring of respiratory, sleep and cardiac parameters, aimed to detect the obstructive events and the following changes in blood oxygen saturation.
Postural OSAS is diagnosed when the obstructive events take place exclusively or mainly in the supine posture and it occurs approximately in 30% of the patients with OSAS. The supine position, mainly due to the effect of gravity on tongue and soft palate position, is usually associated with an increased number of apnoeas and hypopnoeas.
This has been the traditional gold standard investigation. Various physiological recordings are taken whilst the patient is asleep overnight. Techniques vary widely but international standards dictate that a PSG involves at least an electroencephalogram (EEG), two electro-oculograms (EOGs) to measure horizontal and vertical eye movements, and an electromyogram (usually placed on the chin) to monitor muscle movement.
At the end of the investigation, the number of apnoea/hypopnoea episodes whilst asleep is quoted as the Apnoea/Hypopnoea Index (AHI). The AHI is used to measure the severity of OSAS and is calculated by the sum of apnoeas and hypopnoeas divided by the number of hours of sleep.
- Mild: AHI = 5-14.9 per hour.
- Moderate: AHI = 15-29.9 per hour.
- Severe: AHI ≥30 per hour.
Restricted availability of PSG and the cost mean that oximetry and limited respiratory monitoring are more widely used for a diagnosis to be made.
- Domiciliary diagnostic systems, such as respiratory multichannel recording, can measure snoring, nasal airflow, position, oximetry and pulse rate and can detect apnoeas and hypopnoeas.
- Thoracic and abdominal binders register reductions in chest movement (hypopnoeas) that fall short of an apnoea and can differentiate between obstructive and central events.
- A nasolaryngoscopy is usually performed for visualisation of the airway and may also help identify the level of obstruction.
- Blood pressure should be undertaken.
- TFTs may be appropriate in patients in whom hypothyroidism is suspected.
- Arterial blood gases may be required in patients presenting with symptoms of cor pulmonale, to rule out daytime hypoxia or hypercapnoea.
- Offer home respiratory polygraphy to people with suspected OSAS.
- If access to home respiratory polygraphy is limited, consider home oximetry for people with suspected OSAS. Take into account that oximetry alone may be inaccurate for differentiating between OSAS and other causes of hypoxaemia in people with heart failure or chronic lung diseases.
- Consider respiratory polygraphy or polysomnography if oximetry results are negative but the person has significant symptoms.
- Consider hospital respiratory polygraphy for people with suspected OSAS if home respiratory polygraphy and home oximetry are impractical or additional monitoring is needed.
- Consider polysomnography if respiratory polygraphy results are negative but symptoms continue.
- Use the results of the sleep study to diagnose OSAS and determine the severity of OSAS (mild, moderate or severe).
- Cardiovascular disease - coronary heart disease, stroke, transient ischaemic attack, congestive heart failure, and cardiac arrhythmia, particularly atrial fibrillation. OSAS is associated with a significant cardiovascular morbidity and mortality.
- Metabolic syndrome.
- Asthma - there is increasing evidence that patients who snore and have severe asthma have an increased risk of developing OSAS.
- Polycystic ovary syndrome.
- Down's syndrome.
- Non-arteritic anterior ischaemic optic neuropathy (sudden loss of vision in one eye due to decreased blood flow to the optic nerve).
- The goal of the treatment is to restore optimal breathing during the night and also to relieve associated symptoms.
- It is becoming increasingly understood that OSAS is a heterogeneous condition which requires a tailored approach to therapy.
- Management needs to be based on a multidisciplinary and holistic approach which includes lifestyle modifications.
- Benefits may be seen in reduction in daytime sleepiness, simulated driving performance, quality of life, blood pressure and mood. Apart from continuous positive airway pressure (CPAP), there is no diminution of vascular risk in patients without daytime sleepiness, or in asymptomatic patients. It is important to communicate to patients exactly what can be achieved, as well as what the treatments involve.
- Successful long-term management of OSAS requires careful patient education, enlistment of the family's support and the adoption of self-management and patient goal-setting principles.
- Weight loss improves symptoms and morbidity in all patients with obesity, and bariatric surgery is an option in severe obesity. Weight loss, however, is rarely curative in itself.
- Smoking cessation should be advocated from a general health perspective; however, again there is no guarantee that this will alleviate OSAS symptoms.
- Alcohol should be avoided in the evening, as should sedative and hypnotic medication, as these all decrease airway dilator function.
Managing rhinitis in people with OSAS
Assess people with nasal congestion and OSAS for underlying allergic or vasomotor rhinitis.
If rhinitis is diagnosed in people with OSAS, offer initial treatment with:
- Topical nasal corticosteroids or antihistamines for allergic rhinitis; or
- Topical nasal corticosteroids for vasomotor rhinitis.
For people with OSAS and persistent rhinitis, consider referral to an Ear, Nose and Throat specialist if:
- Symptoms do not improve with initial treatment; or
- Anatomical obstruction is suspected.
- CPAP is still recognised as the gold standard treatment. Nasal CPAP (nCPAP) is highly effective in controlling symptoms, improving quality of life and reducing the clinical sequelae of sleep apnoea.
- CPAP acts as a pneumatic splint, maintaining upper airway patency. A flow generator delivers pressure through air tubing to a nasal or facial mask worn overnight. Most patients require lifelong therapy.
- CPAP needs to be worn for a minimum of four hours each night. However, CPAP can lead to claustrophobia, rhinitis, nasal irritation and also disturbance to partners, so that patient compliance can become a problem.
- The efficacy of CPAP strictly depends on its constant use and that a recurrence of symptoms usually occurs after a few days from treatment interruption.
- Bi-level PAP provides two different levels of pressure (higher during inhalation and lower during expiration) and is an alternative in patients intolerant to CPAP and also in patients with associated hypoventilation or chronic obstructive pulmonary disease.
- The role of pharmacological agents is limited. Modafinil may afford some benefit in patients with daytime sleepiness who are compliant with CPAP treatment but has a significant association with adverse events. Longer-term studies are needed.
- Medication such as leukotriene antagonists and topical nasal steroids can be beneficial for children with mild forms of OSAS and also in children with associated allergic diseases.
- A Cochrane review has concluded that there was insufficient current evidence to recommend the use of drug therapy in the treatment of OSAS.
Mandibular advancement splints
Oral appliances have gained increasing recognition as a useful alternative to CPAP for the treatment of patients with mild-to-moderate OSAS and for those patients with severe disease intolerant to CPAP. The most commonly used oral appliances are mandibular advanced splints. These devices attach to both the upper and lower dental arches in order to advance and retain the mandible in a forward position.
Treatment with these splints is safe. Transient side-effects are common and can include excessive salivation, dry mouth and gingival irritation. Side-effects that are more persistent include arthralgia, teeth pain and occlusal changes.
- For people with moderate or severe OSAS who are unable to tolerate or decline to try CPAP, a customised or semi-customised mandibular advancement splint can be used as an alternative to CPAP if they are aged 18 and over and have optimal dental and periodontal health.
- Semi-customised mandibular advancement splints may be inappropriate for people with:
- Active periodontal disease or untreated dental decay.
- Few or no teeth.
- Generalised tonic-clonic seizures.
Positional therapy can be beneficial for those with postural OSAS. This should prevent them from sleeping in the supine posture. Many positional therapy strategies are available. These include the simple 'tennis ball technique', consisting of a tennis ball strapped to the back to discourage supine position, supine alarm devices and a number of positional pillows.
A positional modifier can be considered for people with mild or moderate positional OSAS if other treatments are unsuitable or not tolerated. Positional modifiers are unlikely to be effective in severe OSAS.
Various surgical techniques have otherwise been tried; however, assessment is difficult due to inconsistency of trial methodology. The evidence base is at best equivocal.
Surgical procedures are usually considered for patients for whom CPAP or oral appliances have failed, or if such treatments are contra-indicated by claustrophobia or dental disease. The procedures evaluated include:
- Uvulopalatopharyngoplasty (UPPP) - patients may be unable to use CPAP subsequently.
- Laser-assisted uvulopalatopharyngoplasty (LAUP).
- Radiofrequency ablation of the tongue base.
- Suspension of the hyoid bone.
- Maxillofacial surgery, which can be considered in exceptional circumstances to achieve advancement of the mandible.
- Tonsillectomy - appropriate for tonsillar enlargement.
- Tracheostomy - may be necessary in very severe OSAS where other treatments fail.
- New, minimally invasive surgical techniques - currently being developed to achieve better patient outcomes and reduce surgical morbidity. This approach is particularly useful in patients who cannot tolerate CPAP and are subject to mild-to-moderate symptoms.
For uncomplicated cases in children, surgical intervention with removal of the tonsils and adenoids can lead to significant improvements.
- Tonsillectomy should be considered for people with OSAS who have large obstructive tonsils and a body mass index (BMI) of less than 35 kg/m2.
- Referral for assessment for oropharyngeal surgery should be considered in people with severe OSAS who have been unable to tolerate CPAP and a customised mandibular advancement splint despite medically supervised attempts.
- Excessive daytime sleepiness may cause accidents in the home, at work and whilst driving.
- OSAS is important from a public health perspective because of the increased risk of cardiovascular morbidity and road traffic incidents.
- Irritability, depression and other psychological consequences may ensue.
- Cardiovascular complications include hypertension, coronary artery disease, congestive cardiac failure.
- OSAS has also been identified as an independent risk factor for stroke[22, 23].
- There is an increased risk of hypertension in patients with OSAS. There is also an increased risk of heart failure in patients with OSAS.
- Patients with OSAS have an increased risk of type 2 diabetes mellitus.
Obstructive sleep apnoea and driving
- All patients with OSAS causing excessive daytime or awake time sleepiness need to cease driving until satisfactory control of symptoms has been attained.
- Those with Group 2 entitlement should also cease driving until satisfactory control of symptoms has been attained, with ongoing compliance with treatment, confirmed by a consultant or specialist opinion.
- However, patients do not need to stop driving or inform the DVLA if they are being investigated for, or have a diagnosis of, sleep apnoea but do not experience symptoms of daytime sleepiness that are of a severity likely to impair driving.
- Patients should inform the DVLA (but not cease driving) if they are successfully using CPAP or mandibular positioning therapy. However, as long as the patient is compliant with treatment and their symptoms are controlled such that they no longer impair driving, their licence should not be affected.
- Untreated OSAS can lead to significant neurocognitive and also cardiovascular morbidity. The cognitive impairment can lead to reduced concentration, accidents and also memory problems.
- For patients who respond to CPAP, the short-term prognosis is excellent. There is a positive benefit in terms of reduction in daytime sleepiness and in snoring and an improvement in cognitive function and general health status after 4-8 weeks of treatment with CPAP.
- Treatment can significantly decrease cardiovascular complications, especially in those patients with severe OSAS.
- CPAP therapy can significantly reduce blood pressure in patients with comorbid hypertension and OSAS.
- The current evidence is in agreement that OSAS treatment decreases all-cause mortality in patients with hypertension.
Further reading and references
Greenstone M, Hack M; Obstructive sleep apnoea. BMJ. 2014 Jun 17348:g3745. doi: 10.1136/bmj.g3745.
Moon K, Punjabi NM, Aurora RN; Obstructive sleep apnea and type 2 diabetes in older adults. Clin Geriatr Med. 2015 Feb31(1):139-47, ix. doi: 10.1016/j.cger.2014.08.023. Epub 2014 Oct 18.
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s; NICE guidance (August 2021)
Badran M, Yassin BA, Fox N, et al; Epidemiology of Sleep Disturbances and Cardiovascular Consequences. Can J Cardiol. 2015 Jul31(7):873-9. doi: 10.1016/j.cjca.2015.03.011. Epub 2015 Mar 12.
Su MS, Zhang HL, Cai XH, et al; Obesity in children with different risk factors for obstructive sleep apnea: a community-based study. Eur J Pediatr. 2015 Aug 28.
Obstructive sleep apnoea syndrome; NICE CKS, August 2021 (UK access only)
Kapur VK, Auckley DH, Chowdhuri S, et al; Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017 Mar 1513(3):479-504. doi: 10.5664/jcsm.6506.
Frank MH, Ravesloot MJ, van Maanen JP, et al; Positional OSA part 1: Towards a clinical classification system for position-dependent obstructive sleep apnoea. Sleep Breath. 2015 May19(2):473-80. doi: 10.1007/s11325-014-1022-9. Epub 2014 Jun 19.
Bidarian-Moniri A, Nilsson M, Rasmusson L, et al; The effect of the prone sleeping position on obstructive sleep apnoea. Acta Otolaryngol. 2015 Jan135(1):79-84. doi: 10.3109/00016489.2014.962183. Epub 2014 Nov 11.
Goyal M, Johnson J; Obstructive Sleep Apnea Diagnosis and Management. Mo Med. 2017 Mar-Apr114(2):120-124.
Spicuzza L, Caruso D, Di Maria G; Obstructive sleep apnoea syndrome and its management. Ther Adv Chronic Dis. 2015 Sep6(5):273-85. doi: 10.1177/2040622315590318.
Damianaki A, Vagiakis E, Sigala I, et al; Tauhe Co-Existence of Obstructive Sleep Apnea and Bronchial Asthma: Revelation of a New Asthma Phenotype? J Clin Med. 2019 Sep 168(9). pii: jcm8091476. doi: 10.3390/jcm8091476.
Slowik JM et al; Obstructive Sleep Apnea. StatPearls 2020.
Mansukhani MP, Kolla BP, Olson EJ, et al; Bilevel positive airway pressure for obstructive sleep apnea. Expert Rev Med Devices. 2014 May11(3):283-94. doi: 10.1586/17434440.2014.900435. Epub 2014 Mar 25.
Chapman JL, Vakulin A, Hedner J, et al; Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis. Eur Respir J. 2016 May47(5):1420-8. doi: 10.1183/13993003.01509-2015. Epub 2016 Feb 4.
Sujanska A, Durdik P, Rabasco J, et al; Surgical and non-surgical therapy of obstructive sleep apnea syndrome in children. Acta Medica (Hradec Kralove). 201457(4):135-41. doi: 10.14712/18059694.2015.78.
Mason M, Welsh EJ, Smith I; Drug therapy for obstructive sleep apnoea in adults. Cochrane Database Syst Rev. 2013 May 315:CD003002. doi: 10.1002/14651858.CD003002.pub3.
Ramar K, Dort LC, Katz SG, et al; Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015. J Clin Sleep Med. 2015 Jul 1511(7):773-827. doi: 10.5664/jcsm.4858.
Marklund M, Carlberg B, Forsgren L, et al; Oral Appliance Therapy in Patients With Daytime Sleepiness and Snoring or Mild to Moderate Sleep Apnea: A Randomized Clinical Trial. JAMA Intern Med. 2015 Aug 1175(8):1278-85. doi: 10.1001/jamainternmed.2015.2051.
Salapatas AM, Bonzelaar LB, Hwang MS, et al; Impact of Minimally Invasive Multilevel Surgery on Mild/Moderate OSA. Otolaryngol Head Neck Surg. 2016 Oct155(4):695-701. doi: 10.1177/0194599816651240. Epub 2016 Jun 14.
Lipford MC, Flemming KD, Calvin AD, et al; Associations between Cardioembolic Stroke and Obstructive Sleep Apnea. Sleep. 2015 Jul 24. pii: sp-00779-14.
Lyons OD, Ryan CM; Sleep Apnea and Stroke. Can J Cardiol. 2015 Jul31(7):918-27. doi: 10.1016/j.cjca.2015.03.014. Epub 2015 Mar 14.
Floras JS; Hypertension and Sleep Apnea. Can J Cardiol. 2015 Jul31(7):889-97. doi: 10.1016/j.cjca.2015.05.003. Epub 2015 May 16.
Lyons OD, Bradley TD; Heart Failure and Sleep Apnea. Can J Cardiol. 2015 Jul31(7):898-908. doi: 10.1016/j.cjca.2015.04.017. Epub 2015 Apr 25.
Sun L, Liu JY, Li LR; Serum YKL-40 levels are associated with type 2 diabetes mellitus in patients with obstructive sleep apnea syndrome. Genet Mol Res. 2015 Aug 314(3):8919-25. doi: 10.4238/2015.August.3.15.
Assessing fitness to drive: guide for medical professionals; Driver and Vehicle Licensing Agency
Position Statement: Driving and Obstructive Sleep Apnoea (OSA)/Obstructive Sleep Apnoea Syndrome (OSAS); British Thoracic Society, 2018. Downloadable pdf file.
Dewan NA, Nieto FJ, Somers VK; Intermittent hypoxemia and OSA: implications for comorbidities. Chest. 2015 Jan147(1):266-74. doi: 10.1378/chest.14-0500.
Marcus JA, Pothineni A, Marcus CZ, et al; The role of obesity and obstructive sleep apnea in the pathogenesis and treatment of resistant hypertension. Curr Hypertens Rep. 2014 Jan16(1):411. doi: 10.1007/s11906-013-0411-y.
Ahmad M, Makati D, Akbar S; Review of and Updates on Hypertension in Obstructive Sleep Apnea. Int J Hypertens. 20172017:1848375. doi: 10.1155/2017/1848375. Epub 2017 Sep 24.